Unlock stock picks and a broker-level newsfeed that powers Wall Street.

IOB - Delayed Quote SEK

BioArctic AB (publ) (0RV2.IL)

185.45
+9.45
+(5.37%)
At close: April 23 at 5:10:30 PM GMT+1
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
257,352
257,352
615,995
228,291
23,146
Cost of Revenue
26,984
26,984
14,988
74,326
55,067
Gross Profit
230,368
230,368
601,007
153,965
-31,921
Operating Expense
458,884
458,884
348,368
161,903
107,932
Operating Income
-228,516
-228,516
252,639
-7,938
-139,853
Net Non Operating Interest Income Expense
38,996
38,996
23,846
1,785
-983
Pretax Income
-189,519
-189,519
276,485
-11,167
-140,511
Tax Provision
-12,440
-12,440
47,237
11
-20,723
Net Income Common Stockholders
-177,079
-177,079
229,248
-11,179
-119,789
Diluted NI Available to Com Stockholders
-177,079
-177,079
229,248
-11,179
-119,789
Basic EPS
-2.00
-2.00
2.60
-0.13
-1.36
Diluted EPS
-2.00
-2.00
2.59
-0.13
-1.36
Basic Average Shares
88,539.50
88,539.50
88,172.31
88,074.30
88,059.99
Diluted Average Shares
88,539.50
88,539.50
88,512.74
88,682.99
88,579.99
Total Operating Income as Reported
-228,514
-228,514
252,639
-17,336
-139,723
Total Expenses
485,868
485,868
363,356
236,229
162,999
Net Income from Continuing & Discontinued Operation
-177,079
-177,079
229,248
-11,179
-119,789
Normalized Income
-177,079
-177,079
229,248
-11,179
-119,782.18
Interest Income
40,845
40,845
34,228
2,535
--
Interest Expense
1,849
1,849
10,382
559
838
Net Interest Income
38,996
38,996
23,846
1,785
-983
EBIT
-187,670
-187,670
286,867
-10,608
-139,673
EBITDA
-187,670
-187,670
286,867
4,025
-126,566
Reconciled Cost of Revenue
26,984
26,984
14,988
74,326
55,067
Reconciled Depreciation
--
--
7,439
14,184
13,045
Net Income from Continuing Operation Net Minority Interest
-177,079
-177,079
229,248
-11,179
-119,789
Total Unusual Items Excluding Goodwill
--
--
--
--
-8
Total Unusual Items
--
--
--
--
-8
Normalized EBITDA
-187,670
-187,670
286,867
4,025
-126,558
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
--
--
-1.18
12/31/2021 - 12/18/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

0WA2.IL Cellectis S.A.
1.3530
+3.13%
 
RGO.SG Regeneron Pharmaceuticals Inc
517.60
+1.37%
 
VX1.HM Vertex Pharmaceuticals Inc
431.15
+1.24%
 
ALCLS.PA Cellectis S.A.
1.3440
+2.44%
 
VRTX.MX Vertex Pharmaceuticals Incorporated
9,360.00
0.00%
 
ADCT ADC Therapeutics SA
1.2900
+4.88%
 
RCUS Arcus Biosciences, Inc.
8.11
+0.25%
 
ANVS Annovis Bio, Inc.
1.5100
+2.72%